Skip to main content

GenePeeks Inks Distribution Pact With India's Core Diagnostics

NEW YORK (GenomeWeb) – GenePeeks, a computational genomics company focused on disease risk analysis, said today that it has signed an exclusive distribution agreement with India's Core Diagnostics.

Under the agreement, Core Diagnostics will exclusively offer GenePeeks' preconception screen and advanced analytics platform in 29 states and seven union territories in India.

GenePeeks, based in Cambridge, Massachusetts, has developed a CLIA-certified preconception screening platform that integrates DNA information from two genetic participants to predict the potential genomes of a future child. For every variant in these hypothetical genomes, the company's platform computes a variant gene dysfunction score that predicts the degree to which any variant, known or novel, reduces normal gene function.

"We look forward to working with the exceptional Core team to address the European bias embedded in traditional screening and help Indian families better understand their risk of conceiving a child with a serious genetic disease," Anne Morriss, Cofounder and CEO of GenePeeks, said in a statement.